NR603 — Complex Adult-Gerontology Final Exam Study Guide
NR603-CEA
Complex Adult-Gerontology
Health-Illness Management
Final Exam Study Guide
200 Questions, Straight Answers & Rationale
Original study content covering standard advanced adult-gerontology practice topics
Units: Cardiovascular • Pulmonary • Renal/Fluid-Electrolyte • Endocrine • Neurological • GI/Hepatic • Hematologic/Oncologic •
Infectious Disease/Sepsis • Musculoskeletal/Rheumatologic • Immune/Autoimmune • Psychiatric/Cognitive •
Pharmacology/Polypharmacy • Diagnostic Reasoning • Genitourinary/Reproductive • Palliative/Ethics/EOL
Unit 1: Advanced Cardiovascular Disorders
Question 1: What is the first-line diagnostic test for a patient presenting with acute chest pain?
Answer: A 12-lead ECG.
Rationale: Rapid ECG interpretation is essential to identify ST-segment changes indicating acute coronary
syndrome and to guide time-sensitive treatment decisions.
Question 2: What ECG findings distinguish STEMI from NSTEMI?
Answer: STEMI shows ST-segment elevation in contiguous leads; NSTEMI shows ST depression or T-wave
inversion without ST elevation.
Rationale: This distinction guides urgency of reperfusion therapy, since STEMI requires emergent
revascularization while NSTEMI is managed with a risk-stratified approach.
Question 3: What is the first-line pharmacologic therapy class for HFrEF (heart failure with reduced ejection
fraction)?
Answer: ACE inhibitors or an ARNI, combined with beta-blockers and a mineralocorticoid receptor antagonist as
part of guideline-directed medical therapy.
Page 1 of 31
, NR603 — Complex Adult-Gerontology Final Exam Study Guide
Rationale: These agents reduce mortality in HFrEF by counteracting the neurohormonal activation that drives
disease progression.
Question 4: What laboratory marker is most useful for diagnosing and monitoring heart failure severity?
Answer: B-type natriuretic peptide (BNP) or NT-proBNP.
Rationale: These peptides are released in response to ventricular wall stretch and correlate with the degree of
volume overload and heart failure severity.
Question 5: What is the target INR range for a patient on warfarin for atrial fibrillation without a mechanical
valve?
Answer: 2.0 to 3.0.
Rationale: This range balances reduction of thromboembolic stroke risk against the risk of bleeding
complications.
Question 6: What scoring system estimates stroke risk in patients with atrial fibrillation?
Answer: The CHA2DS2-VASc score.
Rationale: This validated tool helps guide decisions about whether anticoagulation therapy is warranted based on
individual stroke risk factors.
Question 7: What is the first-line treatment for stable, symptomatic bradycardia?
Answer: Atropine.
Rationale: Atropine blocks vagal tone on the SA node, increasing heart rate as a rapid first-line intervention
before considering pacing.
Question 8: What key clinical feature differentiates unstable from stable angina?
Answer: Unstable angina occurs at rest or with minimal exertion, is new-onset, or is increasing in
frequency/severity, unlike predictable, exertional stable angina.
Rationale: These features indicate plaque instability and a higher risk of progression to myocardial infarction,
requiring urgent evaluation.
Question 9: What is the mechanism of action of statins in managing cardiovascular risk?
Answer: They inhibit HMG-CoA reductase, reducing hepatic cholesterol synthesis and lowering LDL levels.
Rationale: Lowering LDL cholesterol reduces atherosclerotic plaque formation and overall cardiovascular event
risk.
Question 10: What is the significance of a new murmur in a patient with fever and a history of IV drug use?
Answer: It raises concern for infective endocarditis.
Rationale: Valvular vegetations from bacterial infection can disrupt normal valve function, producing a new or
changed murmur.
Question 11: What diagnostic framework is used to confirm infective endocarditis?
Answer: The modified Duke criteria, incorporating blood culture and echocardiography findings.
Rationale: Combining microbiologic and imaging criteria improves diagnostic accuracy for this complex, high-
mortality condition.
Question 12: What ECG finding is classic for pericarditis?
Answer: Diffuse ST-segment elevation with PR-segment depression.
Rationale: Diffuse rather than localized changes reflect global pericardial inflammation rather than a focal
coronary event.
Question 13: What is the first-line risk factor modification approach for peripheral arterial disease?
Answer: Smoking cessation, statin therapy, antiplatelet therapy, and supervised exercise.
Page 2 of 31
, NR603 — Complex Adult-Gerontology Final Exam Study Guide
Rationale: These interventions address the underlying atherosclerotic process and improve functional walking
distance and cardiovascular outcomes.
Question 14: What is the significance of an ankle-brachial index (ABI) below 0.90?
Answer: It indicates peripheral arterial disease.
Rationale: A reduced ABI reflects diminished arterial blood flow to the lower extremities relative to the arms,
consistent with arterial obstruction.
Page 3 of 31
, NR603 — Complex Adult-Gerontology Final Exam Study Guide
Unit 2: Advanced Pulmonary Disorders
Question 15: What spirometry finding confirms a diagnosis of COPD?
Answer: A post-bronchodilator FEV1/FVC ratio less than 0.70.
Rationale: This ratio reflects persistent airflow limitation that is not fully reversible, the hallmark diagnostic
feature of COPD.
Question 16: What is the GOLD classification system used for?
Answer: Staging COPD severity based on spirometry (FEV1) and symptom/exacerbation risk.
Rationale: Staging guides the intensity of pharmacologic and nonpharmacologic treatment decisions in COPD
management.
Question 17: What is the first-line long-term pharmacologic treatment for stable, symptomatic COPD?
Answer: A long-acting bronchodilator, either a LABA or LAMA.
Rationale: Long-acting bronchodilators improve airflow and reduce exacerbation frequency more effectively than
short-acting agents alone for maintenance therapy.
Question 18: What is the significance of blood eosinophil count in COPD treatment decisions?
Answer: Elevated blood eosinophils help identify patients more likely to benefit from adding inhaled
corticosteroids to therapy.
Rationale: Eosinophilic inflammation is more responsive to corticosteroid therapy, guiding personalized
treatment selection.
Question 19: How do spirometry findings differ between asthma and COPD?
Answer: Asthma typically shows significant reversibility with a bronchodilator (>12% and 200 mL improvement in
FEV1), while COPD shows limited reversibility.
Rationale: This distinction helps differentiate the two obstructive diseases, which have overlapping symptoms but
different underlying pathophysiology.
Question 20: What determines the stepwise approach to asthma pharmacotherapy?
Answer: Symptom control and exacerbation frequency, following an algorithm from as-needed SABA/ICS up
through combination controller therapy.
Rationale: This approach ensures treatment intensity matches disease severity while minimizing unnecessary
medication burden.
Question 21: What is the diagnostic gold standard for confirming pulmonary embolism?
Answer: CT pulmonary angiography.
Rationale: This imaging modality directly visualizes filling defects within the pulmonary arteries, providing high
sensitivity and specificity for PE diagnosis.
Question 22: What clinical decision tool helps determine the pretest probability of pulmonary embolism?
Answer: The Wells score.
Rationale: This scoring system stratifies risk and helps guide whether D-dimer testing or direct imaging is the
appropriate next diagnostic step.
Question 23: What is the significance of a negative D-dimer in a low-probability patient for PE?
Answer: It effectively rules out PE, avoiding the need for further imaging.
Rationale: D-dimer has high sensitivity but low specificity, so its main clinical value is a negative result in low-risk
patients.
Page 4 of 31
NR603-CEA
Complex Adult-Gerontology
Health-Illness Management
Final Exam Study Guide
200 Questions, Straight Answers & Rationale
Original study content covering standard advanced adult-gerontology practice topics
Units: Cardiovascular • Pulmonary • Renal/Fluid-Electrolyte • Endocrine • Neurological • GI/Hepatic • Hematologic/Oncologic •
Infectious Disease/Sepsis • Musculoskeletal/Rheumatologic • Immune/Autoimmune • Psychiatric/Cognitive •
Pharmacology/Polypharmacy • Diagnostic Reasoning • Genitourinary/Reproductive • Palliative/Ethics/EOL
Unit 1: Advanced Cardiovascular Disorders
Question 1: What is the first-line diagnostic test for a patient presenting with acute chest pain?
Answer: A 12-lead ECG.
Rationale: Rapid ECG interpretation is essential to identify ST-segment changes indicating acute coronary
syndrome and to guide time-sensitive treatment decisions.
Question 2: What ECG findings distinguish STEMI from NSTEMI?
Answer: STEMI shows ST-segment elevation in contiguous leads; NSTEMI shows ST depression or T-wave
inversion without ST elevation.
Rationale: This distinction guides urgency of reperfusion therapy, since STEMI requires emergent
revascularization while NSTEMI is managed with a risk-stratified approach.
Question 3: What is the first-line pharmacologic therapy class for HFrEF (heart failure with reduced ejection
fraction)?
Answer: ACE inhibitors or an ARNI, combined with beta-blockers and a mineralocorticoid receptor antagonist as
part of guideline-directed medical therapy.
Page 1 of 31
, NR603 — Complex Adult-Gerontology Final Exam Study Guide
Rationale: These agents reduce mortality in HFrEF by counteracting the neurohormonal activation that drives
disease progression.
Question 4: What laboratory marker is most useful for diagnosing and monitoring heart failure severity?
Answer: B-type natriuretic peptide (BNP) or NT-proBNP.
Rationale: These peptides are released in response to ventricular wall stretch and correlate with the degree of
volume overload and heart failure severity.
Question 5: What is the target INR range for a patient on warfarin for atrial fibrillation without a mechanical
valve?
Answer: 2.0 to 3.0.
Rationale: This range balances reduction of thromboembolic stroke risk against the risk of bleeding
complications.
Question 6: What scoring system estimates stroke risk in patients with atrial fibrillation?
Answer: The CHA2DS2-VASc score.
Rationale: This validated tool helps guide decisions about whether anticoagulation therapy is warranted based on
individual stroke risk factors.
Question 7: What is the first-line treatment for stable, symptomatic bradycardia?
Answer: Atropine.
Rationale: Atropine blocks vagal tone on the SA node, increasing heart rate as a rapid first-line intervention
before considering pacing.
Question 8: What key clinical feature differentiates unstable from stable angina?
Answer: Unstable angina occurs at rest or with minimal exertion, is new-onset, or is increasing in
frequency/severity, unlike predictable, exertional stable angina.
Rationale: These features indicate plaque instability and a higher risk of progression to myocardial infarction,
requiring urgent evaluation.
Question 9: What is the mechanism of action of statins in managing cardiovascular risk?
Answer: They inhibit HMG-CoA reductase, reducing hepatic cholesterol synthesis and lowering LDL levels.
Rationale: Lowering LDL cholesterol reduces atherosclerotic plaque formation and overall cardiovascular event
risk.
Question 10: What is the significance of a new murmur in a patient with fever and a history of IV drug use?
Answer: It raises concern for infective endocarditis.
Rationale: Valvular vegetations from bacterial infection can disrupt normal valve function, producing a new or
changed murmur.
Question 11: What diagnostic framework is used to confirm infective endocarditis?
Answer: The modified Duke criteria, incorporating blood culture and echocardiography findings.
Rationale: Combining microbiologic and imaging criteria improves diagnostic accuracy for this complex, high-
mortality condition.
Question 12: What ECG finding is classic for pericarditis?
Answer: Diffuse ST-segment elevation with PR-segment depression.
Rationale: Diffuse rather than localized changes reflect global pericardial inflammation rather than a focal
coronary event.
Question 13: What is the first-line risk factor modification approach for peripheral arterial disease?
Answer: Smoking cessation, statin therapy, antiplatelet therapy, and supervised exercise.
Page 2 of 31
, NR603 — Complex Adult-Gerontology Final Exam Study Guide
Rationale: These interventions address the underlying atherosclerotic process and improve functional walking
distance and cardiovascular outcomes.
Question 14: What is the significance of an ankle-brachial index (ABI) below 0.90?
Answer: It indicates peripheral arterial disease.
Rationale: A reduced ABI reflects diminished arterial blood flow to the lower extremities relative to the arms,
consistent with arterial obstruction.
Page 3 of 31
, NR603 — Complex Adult-Gerontology Final Exam Study Guide
Unit 2: Advanced Pulmonary Disorders
Question 15: What spirometry finding confirms a diagnosis of COPD?
Answer: A post-bronchodilator FEV1/FVC ratio less than 0.70.
Rationale: This ratio reflects persistent airflow limitation that is not fully reversible, the hallmark diagnostic
feature of COPD.
Question 16: What is the GOLD classification system used for?
Answer: Staging COPD severity based on spirometry (FEV1) and symptom/exacerbation risk.
Rationale: Staging guides the intensity of pharmacologic and nonpharmacologic treatment decisions in COPD
management.
Question 17: What is the first-line long-term pharmacologic treatment for stable, symptomatic COPD?
Answer: A long-acting bronchodilator, either a LABA or LAMA.
Rationale: Long-acting bronchodilators improve airflow and reduce exacerbation frequency more effectively than
short-acting agents alone for maintenance therapy.
Question 18: What is the significance of blood eosinophil count in COPD treatment decisions?
Answer: Elevated blood eosinophils help identify patients more likely to benefit from adding inhaled
corticosteroids to therapy.
Rationale: Eosinophilic inflammation is more responsive to corticosteroid therapy, guiding personalized
treatment selection.
Question 19: How do spirometry findings differ between asthma and COPD?
Answer: Asthma typically shows significant reversibility with a bronchodilator (>12% and 200 mL improvement in
FEV1), while COPD shows limited reversibility.
Rationale: This distinction helps differentiate the two obstructive diseases, which have overlapping symptoms but
different underlying pathophysiology.
Question 20: What determines the stepwise approach to asthma pharmacotherapy?
Answer: Symptom control and exacerbation frequency, following an algorithm from as-needed SABA/ICS up
through combination controller therapy.
Rationale: This approach ensures treatment intensity matches disease severity while minimizing unnecessary
medication burden.
Question 21: What is the diagnostic gold standard for confirming pulmonary embolism?
Answer: CT pulmonary angiography.
Rationale: This imaging modality directly visualizes filling defects within the pulmonary arteries, providing high
sensitivity and specificity for PE diagnosis.
Question 22: What clinical decision tool helps determine the pretest probability of pulmonary embolism?
Answer: The Wells score.
Rationale: This scoring system stratifies risk and helps guide whether D-dimer testing or direct imaging is the
appropriate next diagnostic step.
Question 23: What is the significance of a negative D-dimer in a low-probability patient for PE?
Answer: It effectively rules out PE, avoiding the need for further imaging.
Rationale: D-dimer has high sensitivity but low specificity, so its main clinical value is a negative result in low-risk
patients.
Page 4 of 31
